Gene Neytman, DO
Internal Medicine · Miami Beach, FLNPI 1003845801
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.8% of the total across 287 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 31 manufacturers reported payments, led by Novo Nordisk at 24.8% of the total. Reporting peaked in 2019 at $1,300 and has fallen 74.2% since, to $335 in 2025. Among internal medicine clinicians in FL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 287 payments — averaging $20.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- AbbVie$886
- Lilly USA, LLC$542
- AstraZeneca$465
- Amarin Pharma, Inc.$398
- Johnson & Johnson$357
- plus $2K from 25 others
Across 237 payments — averaging $18,721 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Organon$1.6M
- Endo Pharmaceuticals Inc.$1.1M
- Urovant Sciences Inc$662K
- Mylan Inc.$531K
- Sumitomo Pharma America, Inc.$386K
- Novavax Inc$90K
- plus $85K from 5 others
What the payments were for
- Food & beverage$5,773100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 66 | $1,435 |
| AbbVie(2 entities) | 57 | $886 |
| Lilly USA, LLC | 34 | $542 |
| AstraZeneca | 24 | $465 |
| Amarin Pharma, Inc. | 15 | $398 |
| Johnson & Johnson | 15 | $357 |
| Redhill Biopharma Inc. | 19 | $327 |
| Bayer | 7 | $307 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $143 |
| Gilead | 4 | $112 |
| Abbott | 4 | $95 |
| Azurity Pharmaceuticals, Inc. | 4 | $93 |
| IBSA Pharma Inc. | 3 | $61 |
| Amgen | 3 | $59 |
| Idorsia Pharmaceuticals US Inc | 3 | $58 |
| Phadia US Inc. | 3 | $55 |
| Sanofi-aventis U.S. LLC | 2 | $48 |
| Merck | 3 | $47 |
| Pfizer | 2 | $35 |
| Exact Sciences | 1 | $35 |
| Alkermes, Inc. | 1 | $28 |
| Halozyme Inc | 1 | $25 |
| Alnylam Pharmaceuticals Inc. | 1 | $24 |
| Antares Pharma, Inc. | 1 | $21 |
| Clarus Therapeutics Inc. | 1 | $21 |
| Heartflow, Inc. | 1 | $20 |
| Nestle Healthcare Nutrition Inc. | 1 | $20 |
| Bausch Health US, LLC | 1 | $19 |
| Tolmar, Inc. | 1 | $18 |
| Currax Pharmaceuticals LLC | 1 | $17 |
| Kowa Pharmaceuticals America, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,785 in reported general payments places this provider in the 90th percentile of 8,530 internal medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 69 | $66,265 |
| MounjaroTirzepatide | 53 | $56,225 |
| VascepaIcosapent Ethyl | 15 | $8,726 |
| CreonLipase/Protease/Amylase | 11 | $5,889 |
| Xigduo XrDapaglifloz Propaned/Metformin | 12 | $4,929 |
| Potassium Citrate ErPotassium Citrate | 77 | $4,228 |
| Clonidine | 20 | $4,128 |
| SynthroidLevothyroxine Sodium | 25 | $2,654 |
| Acetazolamide | 63 | $2,194 |
| Metformin Hcl | 315 | $2,066 |
| Omega-3 Acid Ethyl Esters | 14 | $1,735 |
| Fluconazole | 88 | $1,681 |
| Levothyroxine Sodium | 106 | $1,180 |
| Disulfiram | 11 | $1,088 |
| Testosterone Cypionate | 23 | $888 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $1,435 | $66,26569 claims |
| Lilly USA, LLCMounjaro | $542 | $56,22553 claims |
| AbbVieCreon, Synthroid | $886 | $8,54336 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,530 internal medicine providers in Florida.
Other internal medicine in Miami Beach
- Jason ShapiroMiami Beach$69K
- Haytham ElgammalMiami$2.2M
- Keith RubinFort Lauderdale$2M
- Michael SensionFort Lauderdale$1M
- Quang NguyenOcala$434K
- Luis Correa LunaSanford$412K
- Michael OleksykFort Myers$365K
- Andrew KuykendallTampa$322K
- Howard FederoffCoconut Grove$302K
- Bianka EperjesiovaGainesville$260K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.